Vivos Therapeutics, Inc. (VVOS)
After hours:
| Previous close | 2.4850 |
| Open | 2.5838 |
| Bid | 2.5100 x 100 |
| Ask | 2.7000 x 100 |
| Day's range | 2.4801 - 2.6100 |
| 52-week range | 2.3700 - 48.7900 |
| Volume | |
| Avg. volume | 212,106 |
| Market cap | 7.724M |
| Beta (5Y monthly) | 7.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.1400 |
| Earnings date | 06 June 2024 - 10 June 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.22 |
GlobeNewswireVivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement
First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in AdultsLITTLETON, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced recei
Insider MonkeyVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript March 28, 2024 Vivos Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-3.05 EPS, expectations were $-1.9. VVOS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone, and […]
Simply Wall St.Vivos Therapeutics Full Year 2023 Earnings: Misses Expectations
Vivos Therapeutics ( NASDAQ:VVOS ) Full Year 2023 Results Key Financial Results Revenue: US$13.8m (down 14% from FY...
